|
Annual Financial Statements 2006: Sales +38%, Net Result for the Year +143%
2006: Sales €18.5M, EBITDA €3.9M, Net Profit for the Year €1.6M
Q1/2007: Sales €4.0M
aap Implantate AG, a medical technology company listed in the Prime Standard Segment on the Frankfurt Stock Exchange and specialized in biomaterials and implants for trauma and joint reconstruction, achieved 38% sales growth in financial year 2006 to €18.5 million (previous year: €13.4 million) and a net profit for the year of €1.6 million (previous year: €655K). The aap Group achieved this growth mainly in the Biomaterials segment (Sales +64% to €12.2 million), which now generates two thirds of aap’s overall sales revenue.
| In EUR million | 2006 | 2005 | Change on year | | Sales revenues | 18.5 | 13.4 | +16% | | EBITDA | 3.9 | 2.3 | +93% | | EBIT/Operating result | 2.2 | 0.9 | n. a. | | EBT | 2.1 | 1.1 | n. a. | | Net profit for the year | 1.6 | 0.7 | n. a. | | Equity (ratio) | 21.6 (77%) | 19.4 (77%) | +25% | | Balance sheet total | 28.0 | 25.1 | +23% | | Employees | 161 | 139 | +28% |
The aap Group earned in financial year 2006 an EBITDA of €3.9 million (previous year: €2.3 million). EBT amounted to €2.1 million and was therefore also well above the previous year’s €1.1 million.
The Group’s EBIT improved to €2.2 million (previous year: €855K). With a balance sheet total of €28.0 million (previous year: €25.1 million), the equity ratio was unchanged at 77%.
Preliminary figures show the aap Group to have totaled approx. €4.0 million in sales in the first quarter of 2007, or about 10% less than the previous year’s Q1 €4.4 million. As previously announced, aap does not anticipate growth in financial year 2007 until the second half. Including the Fame Medical Group, Q1 sales were about €6.0 million.
Five suits have been filed by shareholders against the resolutions adopted at the Extraordinary General Meeting held on February 15, 2007, with the result that the commercial register entry of the capital increase approved by the meeting (by 99.6% of votes present) to finance the takeover of the Dutch Fame Medical Group is likely to be delayed. aap will, however, take all the necessary legal steps to ensure that the register entry and the formal takeover are completed as soon as possible.
The consolidated annual financial statements of aap Implantate AG are available in full to download at www.aap.de. Publication of the report for the first quarter of 2007 is scheduled for May 31, 2007.
For further information, please contact:
aap Implantate AG | | Lorenzweg 5 | | D-12099 Berlin | | X | | Oliver Bielenstein | Nanette Hüdepohl | | Director/CFO | Investor & Public Relations | | Tel.: +49 30 750 19 - 140 | Tel.: +49 30 75019 - 133 | | Fax: +49 30 750 19 - 290 | Fax: +49 30 75019 - 290 | | X | | WKN 506660, ISIN DE0005066609 | | Prime Standard/Regulated Market | | Traded at all German Stock Exchanges |
|
Print this page
